JP4593783B2 - 抗ｃ型肝炎ウイルス抗体およびその使用 - Google Patents

抗ｃ型肝炎ウイルス抗体およびその使用 Download PDF

Info

Publication number
JP4593783B2
JP4593783B2 JP2000561222A JP2000561222A JP4593783B2 JP 4593783 B2 JP4593783 B2 JP 4593783B2 JP 2000561222 A JP2000561222 A JP 2000561222A JP 2000561222 A JP2000561222 A JP 2000561222A JP 4593783 B2 JP4593783 B2 JP 4593783B2
Authority
JP
Japan
Prior art keywords
antibody
cells
antibodies
polynucleotide
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000561222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002521391A5 (enExample
JP2002521391A (ja
Inventor
クリスティアン・ライター
フランソワ・ハベルセッツァー
アンヌ・フールニリエ
クリスティアン・トレポ
クロード・デスグランジェ
ジェネヴィエーヴ・アンシャスペ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Genmab AS
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Genmab AS
Publication of JP2002521391A publication Critical patent/JP2002521391A/ja
Publication of JP2002521391A5 publication Critical patent/JP2002521391A5/ja
Application granted granted Critical
Publication of JP4593783B2 publication Critical patent/JP4593783B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000561222A 1998-07-21 1999-07-20 抗ｃ型肝炎ウイルス抗体およびその使用 Expired - Fee Related JP4593783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98113595 1998-07-21
EP98113595.7 1998-07-21
PCT/EP1999/005173 WO2000005266A1 (en) 1998-07-21 1999-07-20 Anti hepatitis c virus antibody and uses thereof

Publications (3)

Publication Number Publication Date
JP2002521391A JP2002521391A (ja) 2002-07-16
JP2002521391A5 JP2002521391A5 (enExample) 2006-08-03
JP4593783B2 true JP4593783B2 (ja) 2010-12-08

Family

ID=8232320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000561222A Expired - Fee Related JP4593783B2 (ja) 1998-07-21 1999-07-20 抗ｃ型肝炎ウイルス抗体およびその使用

Country Status (7)

Country Link
US (3) US6951646B1 (enExample)
EP (1) EP1097172A1 (enExample)
JP (1) JP4593783B2 (enExample)
CN (2) CN1325517C (enExample)
AU (1) AU5285899A (enExample)
CA (1) CA2339045A1 (enExample)
WO (1) WO2000005266A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001232267A1 (en) * 2000-02-14 2001-08-20 Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases Remedies for hepatitis c
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
EP1178116A1 (en) * 2000-08-03 2002-02-06 Hybrigenics S.A. Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
GB0021859D0 (en) * 2000-09-06 2000-10-18 Imp College Innovations Ltd Methods
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
RU2353399C2 (ru) * 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
EP2336176B1 (en) 2003-04-01 2015-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against hepatitis c virus e1e2 complex, and their epitopes
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
EP1765869B1 (en) * 2004-07-08 2015-05-20 JV Bio S.r.l Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication
DE602006014720D1 (de) * 2005-10-07 2010-07-15 Proyecto Biomedicina Cima Sl Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
CN103172743B (zh) 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
JP5642972B2 (ja) 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
EP3153524B1 (en) 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
CN102596996B (zh) * 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
BR112012029881A2 (pt) 2010-05-25 2019-09-24 Inserm (Institut National De La Santé De La Recherche Médicale) combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN103308697B (zh) * 2013-06-09 2014-11-26 卫生部北京医院 检测抗丙型肝炎病毒编码的非结构蛋白ns3和ns5的天然双特异性抗体的试剂盒
CN103472233A (zh) * 2013-06-21 2013-12-25 温州大学 丙型肝炎检测试剂盒及其应用
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
CN104974246A (zh) * 2014-04-01 2015-10-14 中国科学院上海巴斯德研究所 一种中和丙型肝炎病毒的全人单克隆抗体及其用途
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN107286238B (zh) * 2017-08-07 2019-11-26 广州泰诺迪生物科技有限公司 抗hcv广谱中和抗体的制备、检测以及应用
MA52945A (fr) 2018-06-22 2021-04-28 Genmab As Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
AU2019310803B2 (en) 2018-07-25 2022-11-03 Innovent Biologics (Suzhou) Co., Ltd. Anti-TIGIT antibody and uses thereof
US12304946B2 (en) * 2018-12-19 2025-05-20 Humabs Biomed Sa Antibodies that neutralize hepatitis B virus and uses thereof
KR20210126559A (ko) 2018-12-20 2021-10-20 비르 바이오테크놀로지, 인코포레이티드 병용 hbv 요법
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
AU2021228061A1 (en) 2020-02-27 2022-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding IL4R and uses thereof
US20230272086A1 (en) 2020-05-12 2023-08-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
EP4259658A4 (en) * 2020-12-10 2024-12-04 Wuxi Biologics Ireland Limited An antibody against p-cadherin and uses thereof
EP4438055A1 (en) 2021-11-25 2024-10-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-siglec-15 antibody and use thereof
EP4495138A1 (en) 2022-03-18 2025-01-22 Beijing Mabworks Biotech Co., Ltd B7-h3-binding antibody and use thereof
CN118684767B (zh) * 2024-06-27 2025-02-18 山东省大健康精准医疗产业技术研究院 一种丙肝核心抗原单链抗体及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE520499C (de) 1929-09-14 1931-03-11 Heinrich Elsner Vorrichtung zum Biegen von Pappe, Fiber u. dgl.
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
SG71728A1 (en) 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US6747136B2 (en) * 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
EP1127170A4 (en) 1998-11-05 2005-04-27 Univ Leland Stanford Junior HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN
US6682909B2 (en) 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof

Also Published As

Publication number Publication date
WO2000005266A1 (en) 2000-02-03
AU5285899A (en) 2000-02-14
EP1097172A1 (en) 2001-05-09
CN101088561A (zh) 2007-12-19
JP2002521391A (ja) 2002-07-16
CN1325517C (zh) 2007-07-11
US7507408B2 (en) 2009-03-24
US20060153833A1 (en) 2006-07-13
CA2339045A1 (en) 2000-02-03
CN1309664A (zh) 2001-08-22
US20090104188A1 (en) 2009-04-23
US6951646B1 (en) 2005-10-04

Similar Documents

Publication Publication Date Title
JP4593783B2 (ja) 抗ｃ型肝炎ウイルス抗体およびその使用
JP3516681B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）ポリペプチド
Burioni et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments
JPH0581600B1 (enExample)
AU2008280057A1 (en) Antibody having inhibitory activity on infection with hepatitis C virus (HCV), and use thereof
JP2022507836A (ja) 新規の抗ジカウイルス抗体及びその使用
WO1993006488A1 (en) Peptide based hepatitis c virus immunoassays
US20140046034A1 (en) Antibody having activity of inhibiting hepatitus c virus (hcv) infection and use thereof
US6924362B2 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
US20090130123A1 (en) Antibodies to west nile virus polypeptides
WO2006100449A1 (en) Improvements in or relating to treatment and prevention of viral infections
US7282205B2 (en) Anti-hepatitis A virus antibodies
JP5033298B2 (ja) Ｃ型肝炎ウイルスｅ２糖蛋白質に対するヒトモノクローナル抗体
AU2002243259A1 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
WO2002059340A1 (en) Immunopolypeptides to hepatitis c virus
US20030211463A1 (en) Major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis e virus
Varaldo et al. Mapping B-Cell Epitopes of Hepatitis C
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090826

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090826

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100616

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100916

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees